Anzeige
Mehr »
Freitag, 20.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P4H | ISIN: SE0023261292 | Ticker-Symbol: 5JD0
Frankfurt
20.03.26 | 08:02
0,363 Euro
-0,96 % -0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EXPRES2ION BIOTECH HOLDING AB Chart 1 Jahr
5-Tage-Chart
EXPRES2ION BIOTECH HOLDING AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,4030,43716:51

Aktuelle News zur EXPRES2ION BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.02.Expres2ion Biotech Holding AB: Expres2ion Announces The Board Of Directors' Intention To Resolve On A Rights Issue Of Units Of Approximately Sek 53 Million207THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,...
► Artikel lesen
19.02.ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the Full-Year and Fourth Quarter of 2025274Hørsholm, Denmark, 19 February 2026 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its full-year and fourth quarter 2025 results. The report is available as an attachment and on ExpreS2ion's...
► Artikel lesen
03.02.ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech announces Redeye initiation of coverage with base case valuation of SEK 28 per share122Hørsholm, Denmark, 3 February 2026 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") today announces that Redeye has initiated equity research coverage of ExpreS2ion. In its initiation...
► Artikel lesen
EXPRES2ION BIOTECH Aktie jetzt für 0€ handeln
03.02.ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial of ES2B-C001156Hørsholm, Denmark, 03 February 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine...
► Artikel lesen
28.01.ExpreS2ion Biotech Holding AB: As Nipah Virus Outbreaks in India Re-emerge, ExpreS2ion Selects Northway Biotech as Manufacturing Partner for Vaccine Program268Hørsholm, Denmark, 28 January 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine...
► Artikel lesen
20.01.EXPRES2ION BIOTECH HOLDING AB: Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN2
19.01.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion to Participate in Key Investor Event in January 20262
19.12.25EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort2
13.11.25ExpreS2ion Biotech Holding AB Q3 Loss Drops-
13.11.25ExpreS2ion Biotech steigert Einkünfte um 36 % - Aktie reagiert mit Kursplus1
13.11.25ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025287Hørsholm, Denmark, 13 November 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its first nine months and third quarter 2025 results. The report is available as an attachment and...
► Artikel lesen
12.11.25ExpreS2ion And Serum Institute Of India Reach Licensing Deal For Malaria Vaccines1
12.11.25EXPRES2ION BIOTECH HOLDING AB: Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines2
12.11.25EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines1
10.11.25EXPRES2ION BIOTECH HOLDING AB: Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases18
07.11.25EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Hereby Changes Certified Advisor to Redeye2
03.11.25EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion to Participate in Key Investor and Industry Events in November 20254
08.10.25EXPRES2ION BIOTECH HOLDING AB: VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase1
06.10.25EXPRES2ION BIOTECH HOLDING AB: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors2
04.09.25ExpreS2ion Biotech Holding AB: ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial221Hørsholm, Denmark, 4 September 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine...
► Artikel lesen
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1